Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Infect Dis ; 29(1): 70-80, 2023 01.
Article in English | MEDLINE | ID: mdl-36573549

ABSTRACT

In 2019, a community-based, cross-sectional carriage survey and a seroprevalence survey of 1,216 persons 1-55 years of age were conducted in rural Vietnam to investigate the mechanism of diphtheria outbreaks. Seroprevalence was further compared with that of an urban area that had no cases reported for the past decade. Carriage prevalence was 1.4%. The highest prevalence, 4.5%, was observed for children 1-5 years of age. Twenty-seven asymptomatic Coerynebacterium diphtheriae carriers were identified; 9 carriers had tox gene-bearing strains, and 3 had nontoxigenic tox gene-bearing strains. Child malnutrition was associated with low levels of diphtheria toxoid IgG, which might have subsequently increased child carriage prevalence. Different immunity patterns in the 2 populations suggested that the low immunity among children caused by low vaccination coverage increased transmission, resulting in symptomatic infections at school-going age, when vaccine-induced immunity waned most. A school-entry booster dose and improved infant vaccination coverage are recommended to control transmissions.


Subject(s)
Corynebacterium diphtheriae , Diphtheria , Child , Infant , Humans , Diphtheria/epidemiology , Diphtheria/prevention & control , Seroepidemiologic Studies , Cross-Sectional Studies , Vietnam/epidemiology , Corynebacterium , Vaccination , Corynebacterium diphtheriae/genetics
2.
ACS Biomater Sci Eng ; 7(9): 4128-4135, 2021 09 13.
Article in English | MEDLINE | ID: mdl-33724792

ABSTRACT

When embedded into a three-dimensional (3D) matrix, cancer stem cells (or cancer-initiating cells) can grow into self-organizing organotypic structures called tumor organoids. During organoid formation, the matrix not only provides structural support but also delivers biochemical signals. Although increasing evidence indicates that the extracellular matrix (ECM) is an essential component of the tumor microenvironment during tumor development and progression, the influence of the ECM on organoid formation has been largely ignored; the ECM has only recently been recognized to play a role in the regulation of cancer cell phenotypes. We reviewed ECM-based hydrogels to tailoring tumor organoids and highlight the potential role of the ECM in the development of recapitulating malignant/invasive tumor organoids with enhanced capacity for in vitro representation of ECM-regulated tumor progression.


Subject(s)
Neoplasms , Organoids , Extracellular Matrix , Humans , Hydrogels , Tumor Microenvironment
3.
Cancer Gene Ther ; 23(6): 162-7, 2016 06.
Article in English | MEDLINE | ID: mdl-27056671

ABSTRACT

Chemokines are key regulators of both innate and adaptive immune responses. CCL4 (macrophage inflammatory protein-1ß, MIP-1ß) is a CC chemokine that has a broad spectrum of target cells including immature dendritic cells, which express the cognate receptor CCR5. We asked whether a plasmid encoding CCL4 is able to improve tumor protection and immune responses in a Her2/neu+ mouse tumor model. Balb/c mice were immunized twice intramuscularly with plasmid DNA on days 1 and 15. On day 25, a tumor challenge was performed with 2 × 10(5) syngeneic Her2/neu+ D2F2/E2 tumor cells. Different groups of mice were vaccinated with pDNA(Her2/neu) plus pDNA(CCL4), pDNA(Her2/neu), pDNA(CCL4) or mock vector alone. Our results show that CCL4 is able to (i) improve tumor protection and (ii) augment a TH1-polarized immune response against Her2/neu. Although Her2/neu-specific humoral and T-cell immune responses were comparable with that induced in previous studies using CCL19 or CCL21 as adjuvants, tumor protection conferred by CCL4 was inferior. Whether this is due to a different spectrum of (innate) immune cells, remains to be clarified. However, combination of CCL19/21 with CCL4 might be a reasonable approach in the future, particularly for DNA vaccination in Her2/neu+ breast cancer in the situation of minimal residual disease.


Subject(s)
Adjuvants, Immunologic , Cancer Vaccines/immunology , Chemokine CCL4 , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Receptor, ErbB-2/genetics , Vaccines, DNA/immunology , Animals , Cancer Vaccines/genetics , Cell Line , Chemokine CCL4/genetics , Disease Models, Animal , Female , Gene Expression , Gene Order , Humans , Immunization , Mammary Neoplasms, Experimental/pathology , Mammary Neoplasms, Experimental/therapy , Mice , Plasmids/genetics , Tumor Burden , Vaccines, DNA/genetics
4.
Cancer Gene Ther ; 19(1): 69-76, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21997231

ABSTRACT

Secondary lymphoid-tissue chemokine (SLC/CCL21) is a CC chemokine that is constitutively expressed in various lymphoid tissues and binds to chemokine receptor CCR7 on mature dendritic cells (DCs) and distinct T-and B-cell sub-populations. In vivo, CCL21 regulates the encounters between DC and T cells and thus is a key regulator of adaptive immune responses. We asked whether CCL21 is able to augment immunogenicity of a DNA-based vaccine against Her2/neu in a Balb/c mouse model with syngeneic Her2/neu+ tumor cells (D2F2/E2). Mice were vaccinated intramuscularly with plasmid DNA (pDNA) on day 1 and boosted on day 15; tumor challenge was performed subcutaneously on day 25. Coexpression of CCL21 and Her-2/neu resulted in induction of a TH1-polarized immune response and substantial improvement of the protective effect of the DNA vaccine. Coexpression of tumor antigen pDNA(Her2/neu) with both pDNA(GM-CSF) and pDNA(CCL21) as adjuvants led to further improvement of protection by the vaccine (70% tumor-free mice on day 35 vs 40% with either adjuvant alone vs 5-10% with tumor antigen alone). Our results show that CCL21 is a potent adjuvant for DNA vaccination, particularly in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical use of a pDNA(Her2/neu/CCL21/GM-CSF) vaccine might be particularly promising in minimal residual Her2/neu+ breast cancer.


Subject(s)
Cancer Vaccines/immunology , Chemokine CCL21/immunology , Mammary Neoplasms, Experimental/prevention & control , Receptor, ErbB-2/immunology , Vaccines, DNA/immunology , Animals , Cancer Vaccines/genetics , Cancer Vaccines/pharmacology , Cell Line, Tumor , Chemokine CCL21/genetics , Disease Models, Animal , Female , Humans , Mammary Neoplasms, Experimental/enzymology , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Mice , Mice, Inbred BALB C , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/genetics , Vaccines, DNA/genetics , Vaccines, DNA/pharmacology
5.
Article in English | MEDLINE | ID: mdl-18003073

ABSTRACT

This paper is concerned with the development of a real-time obstacle avoidance system for an autonomous wheelchair using stereoscopic cameras by severely disabled people. Based on the left and right images captured from stereoscopic cameras mounted on the wheelchair, the optimal disparity is computed using the Sum of Absolute Differences (SAD) correlation method. From this disparity, a 3D depth map is constructed based on a geometric projection algorithm. A 2D map converted from this 3D map can then be employed to provide an effective obstacle avoidance strategy for this wheelchair. Experiment results obtained in a practical environment show the effectiveness of this real-time implementation.


Subject(s)
Avoidance Learning , Disabled Persons/rehabilitation , Personal Autonomy , Wheelchairs , Algorithms , Computer Systems , Cybernetics , Humans , Photography , Vision Disparity
SELECTION OF CITATIONS
SEARCH DETAIL
...